Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS).
Weiping Jia, Jianhua Ma, Heng Miao, Changjiang Wang, Xiaoyue Wang, Quanmin Li, Weiping Lu, Jialin Yang, Lihui Zhang, Jinkui Yang, Guixia Wang, Xiuzhen Zhang, Min Zhang, Li Sun, Xuefeng Yu, Jianling Du, Bingyin Shi, Changqing Xiao, Dalong Zhu, Hong Liu, Liyong Zhong, Chun Xu, Qi Xu, Ganxiong Liang, Ying Zhang, Guangwei Li, Mingyu Gu, Jun Liu, Guoyue Yuan, Zhaoli Yan, Dewen Yan, Shandong Ye, Fan Zhang, Zhiqiang Ning, Haixiang Cao, Desi Pan, He Yao, Xianping Lu, Linong Ji
Science bulletin 2023;66(15):1581-1590